Dihydroartemisinin inhibits activation of the AIM2 inflammasome pathway and NF-κB/HIF-1α/VEGF pathway by inducing autophagy in A431 human cutaneous squamous cell carcinoma cells

Int J Med Sci. 2021 May 13;18(12):2705-2715. doi: 10.7150/ijms.57167. eCollection 2021.

Abstract

The therapeutic effect of dihydroartemisinin (DHA) against cutaneous squamous cell carcinoma (cSCC) has been previously demonstrated; however, the underlying mechanism remains unclear. This study sought to verify the therapeutic effect of DHA against cSCC and explore its underlying mechanism in A431 cSCC cells. This study reported that DHA inhibited A431 cells proliferation in a time- and concentration-dependent manner and promoted A431 cells apoptosis. Moreover, DHA inhibited the invasion and migration of A431 cells. Mechanistically, DHA promoted autophagy and inhibited activation of the absent in melanoma 2 (AIM2) inflammasome pathway and NF-κB/HIF-1α/VEGF pathway. Treatment of A431 cells with the mTOR inhibitor, and autophagy promoter, rapamycin also inhibited these two pathways. In conclusion, DHA inhibited activation of the AIM2 inflammasome pathway and NF-κB/HIF-1α/VEGF pathway by promoting autophagy in A431 cells, thus accounting for its therapeutic effect. Induction of autophagy by DHA may be mediated by inhibiting the mTOR pathway and promoting reactive oxygen species production.

Keywords: AIM2 inflammasome pathway; NF-κB/HIF-1α/VEGF pathway; autophagy; cutaneous squamous cell carcinoma; dihydroartemisinin.

MeSH terms

  • Apoptosis / drug effects
  • Apoptosis / immunology
  • Artemisinins / pharmacology*
  • Artemisinins / therapeutic use
  • Autophagy / drug effects
  • Autophagy / immunology
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / immunology
  • Carcinoma, Squamous Cell / pathology
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Movement / immunology
  • Cell Proliferation / drug effects
  • Drug Screening Assays, Antitumor
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Inflammasomes / drug effects*
  • Inflammasomes / immunology
  • Inflammasomes / metabolism
  • NF-kappa B / metabolism
  • Signal Transduction / drug effects
  • Signal Transduction / immunology
  • Sirolimus / pharmacology
  • Sirolimus / therapeutic use
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / metabolism
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Artemisinins
  • HIF1A protein, human
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Inflammasomes
  • NF-kappa B
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • artenimol
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus